TY - JOUR
T1 - L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis
AU - Schauer, Stephanie N.
AU - Carreira, Patricia E.
AU - Shukla, Ruchi
AU - Gerhardt, Daniel J.
AU - Gerdes, Patricia
AU - Sanchez-Luque, Francisco J.
AU - Nicoli, Paola
AU - Kindlova, Michaela
AU - Ghisletti, Serena
AU - Dos Santos, Alexandre D.
AU - Rapoud, Delphine
AU - Samuel, Didier
AU - Faivre, Jamila
AU - Ewing, Adam D.
AU - Richardson, Sandra R.
AU - Faulkner, Geoffrey J.
N1 - Funding Information:
Pr. Denis Castaing, Pr. Antonio Sa Cunha, and Pr. Eric Vibert, who are surgeons in the Centre Hépatobiliaire, Villejuif, and the Tissue Biobank Group (AP-HP and Université Paris-Sud) for providing human specimens. We thank members of the Faulkner laboratory for helpful advice and discussion. This study was supported by CSL Centenary Fellowship and National Health and Medical Research Council (NHMRC) Project Grant (GNT1042449, GNT1045991, GNT1067983, GNT1068789, and GNT1106206) funding to G.J.F., the EU FP7 under grant agreement No. 259743 underpinning the MODHEP consortium to J.F., D.S., and G.J.F., and an Australian Research Council Discovery Early Career Researcher Award (DE150101117) to A.D.E.
Funding Information:
We thank Pr. John V. Moran for the plasmids pJM101/L1.3 and pJM105/L1.3, and Pr. Haig H. Kazazian for the plasmids pTN201 and TGF21. We thank Pr. René Adam, Pr. Daniel Cherqui, Pr. Denis Castaing, Pr. Antonio Sa Cunha, and Pr. Eric Vibert, who are surgeons in the Centre Hépatobiliaire, Villejuif, and the Tissue Biobank Group (AP-HP and Université Paris-Sud) for providing human specimens. We thank members of the Faulkner laboratory for helpful advice and discussion. This study was supported by CSL Centenary Fellowship and National Health and Medical Research Council (NHMRC) Project Grant (GNT1042449, GNT1045991, GNT1067983, GNT1068789, and GNT1106206) funding to G.J.F., the EU FP7 under grant agreement No. 259743 underpinning the MODHEP consortium to J.F., D.S., and G.J.F., and an Australian Research Council Discovery Early Career Researcher Award (DE150101117) to A.D.E.
Publisher Copyright:
© 2018 Schauer et al.
PY - 2018/5
Y1 - 2018/5
N2 - The retrotransposon Long Interspersed Element 1 (LINE-1 or L1) is a continuing source of germline and somatic mutagenesis in mammals. Deregulated L1 activity is a hallmark of cancer, and L1 mutagenesis has been described in numerous human malignancies. We previously employed retrotransposon capture sequencing (RC-seq) to analyze hepatocellular carcinoma (HCC) samples from patients infected with hepatitis B or hepatitis C virus and identified L1 variants responsible for activating oncogenic pathways. Here, we have applied RC-seq and whole-genome sequencing (WGS) to an Abcb4 (Mdr2)−/− mouse model of hepatic carcinogenesis and demonstrated for the first time that L1 mobilization occurs in murine tumors. In 12 HCC nodules obtained from 10 animals, we validated four somatic L1 insertions by PCR and capillary sequencing, including TF subfamily elements, and one GF subfamily example. One of the TF insertions carried a 3′ transduction, allowing us to identify its donor L1 and to demonstrate that this full-length TF element retained retrotransposition capacity in cultured cancer cells. Using RC-seq, we also identified eight tumor-specific L1 insertions from 25 HCC patients with a history of alcohol abuse. Finally, we used RC-seq and WGS to identify three tumor-specific L1 insertions among 10 intra-hepatic cholangiocarcinoma (ICC) patients, including one insertion traced to a donor L1 on Chromosome 22 known to be highly active in other cancers. This study reveals L1 mobilization as a common feature of hepatocarcinogenesis in mammals, demonstrating that the phenomenon is not restricted to human viral HCC etiologies and is encountered in murine liver tumors.
AB - The retrotransposon Long Interspersed Element 1 (LINE-1 or L1) is a continuing source of germline and somatic mutagenesis in mammals. Deregulated L1 activity is a hallmark of cancer, and L1 mutagenesis has been described in numerous human malignancies. We previously employed retrotransposon capture sequencing (RC-seq) to analyze hepatocellular carcinoma (HCC) samples from patients infected with hepatitis B or hepatitis C virus and identified L1 variants responsible for activating oncogenic pathways. Here, we have applied RC-seq and whole-genome sequencing (WGS) to an Abcb4 (Mdr2)−/− mouse model of hepatic carcinogenesis and demonstrated for the first time that L1 mobilization occurs in murine tumors. In 12 HCC nodules obtained from 10 animals, we validated four somatic L1 insertions by PCR and capillary sequencing, including TF subfamily elements, and one GF subfamily example. One of the TF insertions carried a 3′ transduction, allowing us to identify its donor L1 and to demonstrate that this full-length TF element retained retrotransposition capacity in cultured cancer cells. Using RC-seq, we also identified eight tumor-specific L1 insertions from 25 HCC patients with a history of alcohol abuse. Finally, we used RC-seq and WGS to identify three tumor-specific L1 insertions among 10 intra-hepatic cholangiocarcinoma (ICC) patients, including one insertion traced to a donor L1 on Chromosome 22 known to be highly active in other cancers. This study reveals L1 mobilization as a common feature of hepatocarcinogenesis in mammals, demonstrating that the phenomenon is not restricted to human viral HCC etiologies and is encountered in murine liver tumors.
UR - http://www.scopus.com/inward/record.url?scp=85046619387&partnerID=8YFLogxK
U2 - 10.1101/gr.226993.117
DO - 10.1101/gr.226993.117
M3 - Article
C2 - 29643204
AN - SCOPUS:85046619387
SN - 1088-9051
VL - 28
SP - 639
EP - 653
JO - Genome Research
JF - Genome Research
IS - 5
ER -